多宁生物三递港交所IPO：2025年前三季度扭亏但净利率仅2.2%

Core Viewpoint - Dongning Biotechnology has submitted its IPO application to the Hong Kong Stock Exchange for the third time, following two previous failed attempts in September 2022 and March 2023, with Morgan Stanley and Huatai International as joint sponsors [1]. Group 1: Company Overview - Dongning Biotechnology, established in 2005, specializes in providing comprehensive solutions for the development and commercialization of biopharmaceutical products, being the first domestic provider of serum-free culture media [1]. - The company ranks sixth among all cell culture media suppliers in China, third among domestic suppliers, and fourth among single-use product suppliers, with a market share of 14.3% [1][3]. Group 2: Financial Performance - In the reporting period, the company achieved revenues of RMB 814.08 million, RMB 842.88 million, and RMB 658.93 million, while incurring annual losses of RMB -314.66 million, RMB -27.5 million, and RMB -8.26 million [2][4]. - Despite revenue growth, the company recorded losses in 2023 and 2024, with a net profit margin of only 2.2% in the first three quarters of 2025 [2]. Group 3: Business Segments - The core business consists of two main segments: bioprocess solutions and laboratory products and services, with bioprocess solutions being the primary revenue driver [1][4]. - The revenue contribution from bioprocess solutions was 77.0%, 75.7%, and 77.1% for 2023, 2024, and the first three quarters of 2025, respectively, indicating its dominance in the company's revenue structure [4]. Group 4: IPO Fund Utilization - The funds raised from the IPO will be primarily used for expanding global market reach, strategic acquisitions and equity investments, enhancing R&D capabilities, upgrading existing production capacity, and supplementing working capital [5]. Group 5: Challenges and Risks - The company faces operational challenges, having recorded losses in 2023 and 2024 due to high expenses and changes in the fair value of financial assets [5]. - WuXi Biologics, a major customer, supplier, and shareholder, has created multiple related-party relationships, and the company's goodwill value reached RMB 843 million by the end of the third quarter of 2025, which may impact future operations and valuations [5].